Ficus Capital

Morpheus Labs is a developer of a blockchain platform-as-a-service that streamlines the creation of blockchain applications. The company focuses on making blockchain technology accessible and efficient for individuals, businesses, and communities. Its proprietary technology stack includes a low-code and AI-driven platform that accelerates end-to-end solution delivery through customizable templates. By providing essential tools, infrastructure, and various blockchain protocols, Morpheus Labs empowers developers to effortlessly build, experiment, and manage their own applications. The company's mission is to promote widespread adoption of blockchain technology while fostering a culture of collaborative innovation.

Simplify, one of the World’s 50 Most Innovative Companies, creates a marketplace for users to buy and sell excess Internet bandwidth from their monthly home broadband and mobile plans. The company extends sharing economy to the broadband space, enabling everyone to be a little Internet Service Provider. The service dynamically creates an encrypted hotspot password so that any buyers can seamlessly piggyback on another person's internet access on the fly. Headquartered in Malaysia, Simplify idea was validated and refined at Massachusetts Institute of Technology (MIT). The technology that powered Simplify has since granted a US Patent.

Assemblr is an augmented reality platform that facilitates the creation, discovery, and sharing of AR experiences. It allows users to visualize information through interactive 3D content, making it accessible to a wide audience. The platform includes both mobile and desktop applications, enabling users to create AR projects or upload custom 3D models from existing software. Users can seamlessly access and share augmented reality content anytime and anywhere. In the near future, Assemblr plans to introduce a monetization feature, allowing users to join the Assemblr Certified Creator program to develop AR projects for others or sell 3D assets in the Assemblr Marketplace for use in AR applications.

Eolo Pharma is a biopharmaceutical company focused on developing molecular drugs aimed at addressing chronic inflammation. The company specializes in the research and development of innovative medicines that target the molecular and cellular mechanisms underlying inflammation-related diseases. By creating disruptive therapies, Eolo Pharma seeks to enhance the healthcare landscape by introducing new treatments for conditions that are among the leading causes of death. Its work is dedicated to providing effective solutions for managing and preventing diseases associated with chronic inflammation.